senl_BCMA / SenlangBio - LARVOL DELTA

High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma (ASH 2023) - P=N/A | "Methods Autologous peripheral blood lymphocytes were collected from patients, who subsequently underwent intravenous fludarabine (30mg/m2/d) and cyclophosphamide (300mg/m2/d) lymphodepletion chemotherapy from day-5 to day -3. Conclusions The clinical trial demonstrated that BCMA CAR-T therapy, composed of dual nanobody VHHs targeting BCMA (dVHHs), exhibits a high ORR with a manageable safety profile in treating R/R MM patients. This extends even to high-risk patients, such as those with extramedullary lesions, cytogenetics high-risk groups, and patients with plasma cell leukemia or anaplastic plasma cell tumor."

CAR T-Cell Therapy • Clinical • IO biomarker • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia • Plasmacytoma • Respiratory Diseases • Transplantation • TP53

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Completed ➔ Recruiting | Trial completion date: Dec 2024 ➔ Dec 2027 | Trial primary completion date: Sep 2024 ➔ Sep 2027

Enrollment open • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • CD4 • CD8

Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma. (PubMed, Blood Adv) - P=N/A | "We explored the use of nanobody-based BCMA(S103) CAR-T cell therapy for R/R plasma cell myeloma (NCT04447573). The one-year OS rate was 61.1%, and PFS was 57.2%. BCMA CAR-T therapy, utilizing dual nanobody VHHs targeting BCMA, demonstrates a high overall response rate (ORR) and manageable safety profile in treating patients with R/R plasmacytic myeloma, including those with high-risk features such as extramedullary lesions, high-risk cytogenetic abnormalities, plasma cell leukemia, or anaplastic plasmacytoma."

IO biomarker • Journal • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Plasma Cell Leukemia • Plasmacytoma • TP53

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients with Hematological Malignancies (clinicaltrials.gov) - P=N/A | N=42 | Completed | Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Recruiting ➔ Completed

Trial completion • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • CD4 • CD8

Clinical Study of CAR-T Technique in the Treatment of Malignant Hematological Tumors (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

New trial • Acute Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • CD4 • CD8 • IL10 • IL6

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1; N=50; Recruiting; Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Clinical • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology